David G. Lambert

ORCID: 0000-0003-4769-8090
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Receptor Mechanisms and Signaling
  • Neuropeptides and Animal Physiology
  • Pain Mechanisms and Treatments
  • Neuroscience and Neuropharmacology Research
  • Ion channel regulation and function
  • Pharmacological Receptor Mechanisms and Effects
  • Cardiovascular, Neuropeptides, and Oxidative Stress Research
  • Anesthesia and Sedative Agents
  • Hormonal Regulation and Hypertension
  • Seismic Waves and Analysis
  • Hypothalamic control of reproductive hormones
  • Seismology and Earthquake Studies
  • Apelin-related biomedical research
  • Cardiac, Anesthesia and Surgical Outcomes
  • Anesthesia and Neurotoxicity Research
  • Cancer, Stress, Anesthesia, and Immune Response
  • Cannabis and Cannabinoid Research
  • Cardiovascular Disease and Adiposity
  • Chemical Synthesis and Analysis
  • Earthquake Detection and Analysis
  • Geophysics and Sensor Technology
  • Anesthesia and Pain Management
  • Pain Management and Opioid Use
  • Cardiac electrophysiology and arrhythmias
  • earthquake and tectonic studies

University of Leicester
2016-2025

Leicester Royal Infirmary
2013-2022

United States Air Force Research Laboratory
2022

United States Air Force
2022

The University of Sydney
2022

University of California, San Diego
2022

Université de Rouen Normandie
2014

Université Européenne de Bretagne
2014

Inserm
2014

Montreal General Hospital
2014

The spectral amplitudes and travel times of seismic body waves are used to determine mantle velocity structures appropriate distinct structural provinces within the western continental United States.In addition basic amplitude time data, travel-time delays P, data from other studies as constraints in systematic inversion for structure.The regional upper determined this manner show collectively rather sharp zones transition (high gradients) near 150, 400, 650 km possibly 1000...

10.1029/jb074i025p05825 article EN Journal of Geophysical Research Atmospheres 1969-11-15

Nociceptin (orphanin FQ) is a novel neuropeptide capable of inducing variety biological actions via activation specific G‐protein coupled receptor. However, the lack selective nociceptin receptor antagonist has hampered our understanding and role this peptide in pathophysiological states. As part broader programme research, geared to identification characterization ligands, we report that [Nphe 1 ]nociceptin(1‐13)NH 2 acts as first truly competitive devoid any residual agonist activity....

10.1038/sj.bjp.0703169 article EN British Journal of Pharmacology 2000-03-01

We have evaluated the efficacy of delta-9-tetrahydrocannabinol (delta-9-THC), main psychoactive constituent cannabis, in postoperative pain. In a randomized double-blind, placebo-controlled, single-dose trial, we investigated 40 women undergoing elective abdominal hysterectomy. Randomization took place when patient-controlled analgesia was discontinued on second day. When patients requested further analgesia, they received single, identical capsule either oral delta-9-THC 5 mg (n=20) or...

10.1016/s0304-3959(03)00331-2 article EN Pain 2003-09-17

Nociceptin/orphanin FQ (N/OFQ) modulates several biological functions by activating a specific G‐protein coupled receptor (NOP). Few molecules are available that selectively activate or block the NOP receptor. Here we describe in vitro and vivo pharmacological profile of novel ligand, [Nphe 1 ,Arg 14 ,Lys 15 ]N/OFQ‐NH 2 (UFP‐101). UFP‐101 binds to human recombinant expressed Chinese hamster ovary (CHO) cells with high affinity (pK i 10.2) shows more than 3000 fold selectivity over classical...

10.1038/sj.bjp.0704706 article EN British Journal of Pharmacology 2002-05-01

This study reports increased intracellular Ca2+ and inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] in response to muscarinic-cholinergic stimulation of human neuroblastoma (SH-SY5Y) cells. Carbachol leads a rapid increase Ins(1,4,5)P3 mass, both reaching peak at around 10 s then declining new maintained phase significantly above basal. Dose-response analysis plateau phases shows different agonist potencies for phases, carbachol being more potent the phase. The plateau-phase was dependent on...

10.1042/bj2650555 article EN Biochemical Journal 1990-01-15

Nociceptin, an endogenous ligand for the orphan receptor ORL1, has recently been described. In this study we have shown that nociception inhibits 46 mM K(+)-stimulated glutamate release from rat perfused cerebrocortical slices with IC50 of 51 nM. At 100 nM inhibition amounted to 68 +/- 14% and was naloxone (10 microM)-insensitive excluding activation mu, delta kappa opioid receptors. These data demonstrate functional coupling ORL1 in glutamatergic neurones implicates a role nociceptin...

10.1111/j.1476-5381.1996.tb16007.x article EN British Journal of Pharmacology 1996-11-01

This paper describes the results of an industry effo rt to test Bio-derived Synthetic Paraffinic Kerosene (Bio-SPK) from natural plant oils. The program included identification and sourcing sustainable feedstocks, use a new fuel processing method, nu merous tests, engine operability, performance emissions flight testing in three Boeing aircraft models. Bio-SPK blended fuels have potential reduce life cycle CO2 be compatible with current aircraft, systems, infrastructure.

10.2514/6.2009-7002 article EN 9th AIAA Aviation Technology, Integration, and Operations Conference (ATIO) 2009-06-14

Background The authors examined the interaction of ketamine with recombinant mu, kappa, and delta opioid receptors orphan expressed in Chinese hamster ovary cells (CHO-mu, CHO-kappa, CHO-delta, CHO(ORL1), respectively). Methods CHO-mu, CHO-delta membranes were incubated receptor radioligand [3H]diprenorphine at room temperature. Ketamine (racemic, R(-) S(+)) was included concentrations covering clinical range. CHO(ORL1) [125I]Tyr(14)nociceptin racemic effects selective agonists (mu: [D-Ala2,...

10.1097/00000542-199901000-00023 article EN Anesthesiology 1999-01-01

Although many different types of compounds have been tested for 5-hydroxytryptamine1A (5-HT1A) binding affinity, much remains to be learned about the structural requirements associated with 5-HT1A agonism, partial and antagonism. The present study uses forskolin-stimulated adenylate cyclase (FSC) assay as a functional screen in rat hippocampal membranes examine structure-activity relationships series enantiomers novel analogs prototypic agonist 8-hydroxy-2-(di-n-propylamino)tetralin...

10.1016/s0026-895x(25)11082-1 article EN Molecular Pharmacology 1991-06-01
Coming Soon ...